BRIEF published on 09/18/2024 at 07:05, 1 year 2 months ago Relief Therapeutics achève la phase clinique de l'étude RLF-OD032 Étude Clinique RLF-OD032 Biodisponibilité Phénylcétonurie Dichlorhydrate De Saproptérine
BRIEF published on 09/18/2024 at 07:05, 1 year 2 months ago Relief Therapeutics Completes Clinical Phase of RLF-OD032 Study Clinical Study Bioavailability RLF-OD032 Phenylketonuria Sapropterin Dihydrochloride
PRESS RELEASE published on 09/18/2024 at 07:00, 1 year 2 months ago Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October 2024 Relief Therapeutics completes clinical phase in RLF-OD032 proof-of-concept study for PKU treatment, expecting topline results in October 2024 Relief Therapeutics RLF-OD032 Proof-of-Concept Study PKU Treatment Topline Results
BRIEF published on 09/02/2024 at 07:05, 1 year 3 months ago Relief Therapeutics annonce la présentation des résultats de l'étude PKU GOLIKE au SSIEM 2024 Essai Clinique PKU GOLIKE THÉRAPEUTIQUE DE SECOURS SSIEM 2024 Phénylcétonurie
BRIEF published on 09/02/2024 at 07:05, 1 year 3 months ago Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024 Clinical Trial Relief Therapeutics PKU GOLIKE SSIEM 2024 Phenylketonuria
PRESS RELEASE published on 09/02/2024 at 07:00, 1 year 3 months ago Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024 Relief Therapeutics announces interim results of PKU GOLIKE study at SSIEM 2024, showing potential benefits for phenylketonuria patients. Study evaluates overnight Phe fluctuations Clinical Trial Relief Therapeutics PKU GOLIKE SSIEM 2024 Phenylketonuria
BRIEF published on 08/30/2024 at 07:05, 1 year 3 months ago Relief Therapeutics publie ses résultats financiers du premier semestre 2024 et une mise à jour de l'entreprise Résultats Financiers Essais Cliniques Mise À Jour De L'entreprise Augmentation Des Revenus Réserves De Trésorerie
BRIEF published on 08/30/2024 at 07:05, 1 year 3 months ago Relief Therapeutics Reports Half-Year 2024 Financial Results and Corporate Update Financial Results Revenue Increase Clinical Trials Corporate Update Cash Reserves
PRESS RELEASE published on 08/30/2024 at 07:00, 1 year 3 months ago Relief Therapeutics Reports Half-Year 2024 Financial Results and Provides Corporate Update Relief Therapeutics reports half-year 2024 financial results and provides corporate update, showcasing operational progress, key development programs, and financial stability Half-year Results Relief Therapeutics Financial Update Development Programs Cash Reserves
BRIEF published on 08/05/2024 at 07:05, 1 year 3 months ago Relief Therapeutics Secures Up to $11 Million from Royalty Sales FDA Approval Clinical Development Relief Therapeutics Non-dilutive Funding Royalty Sales
Published on 12/05/2025 at 02:35, 4 hours 5 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 5 hours 40 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 7 hours 35 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 7 hours 40 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 03:30, 3 hours 10 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 6 hours 49 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 10 hours 15 minutes ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 10 hours 25 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 11 hours 30 minutes ago SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance
Published on 12/04/2025 at 18:14, 12 hours 25 minutes ago Résiliation d'une convention conclue entre actionnaires
Published on 12/04/2025 at 18:00, 12 hours 40 minutes ago Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 28 novembre 2025
Published on 12/04/2025 at 18:00, 12 hours 40 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 12 hours 55 minutes ago Informations relatives au nombre total de droits de vote et d’actions
Published on 12/04/2025 at 17:45, 12 hours 55 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
